|Ms. Karen Pignet-Aiach MBA||Founder, Chairman & CEO||493.28k||N/A||1971|
|Mr. Stephane Durant des Aulnois||Admin. & Financial Director||N/A||N/A||N/A|
|Dr. Ralph Laufer||Chief Scientific Officer||N/A||N/A||N/A|
|Dr. Michaël Hocquemiller Ph.D.||Head of Non-Clinical Devel.||N/A||N/A||N/A|
|Dr. Marie Deneux||Chief Regulatory affairs||N/A||N/A||N/A|
Lysogene S.A., a biopharmaceutical gene therapy company, focuses on the discovery and development of therapies for children with neurodegenerative lysosomal storage disorders. Its clinical programs include LYS-SAF302, which is in Phase II/III clinical trial for the treatment of mucopolysaccharidosis type IIIA; and LYS-GM101 that is in Phase I/II trial for the treatment of GM1 gangliosidosis. The company has a collaborative research collaboration with the Weizmann Institute of Science for developing a novel AAV gene therapy approach for neuronopathic gaucher disease, parkinson disease, and other diseases. Lysogene S.A. was incorporated in 2009 and is based in Neuilly-sur-Seine, France.
Lysogene S.A.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.